CSL pays $355M upfront to co-develop Alentis' anti-Claudin-1 antibody lixudebart
- CSL will pay $355 million upfront, plus up to $1.2 billion in commercial milestones, to co-develop and co-commercialize the anti-Claudin-1 antibody lixudebart.
- Profits split 55% CSL and 45% Alentis; CSL funds the ongoing phase 2 in ANCA-associated vasculitis with rapidly progressive glomerulonephritis and a phase 3.
- Phase 2 studies in focal segmental glomerulosclerosis and primary sclerosing cholangitis are also planned.
💡 Points
A 55/45 profit split with a $355M upfront is unusually rich for a phase 2 asset, and it tells me CSL wants a nephrology franchise on real terms. Alentis keeps a meaningful economic stake instead of a royalty. The multi-indication plan across kidney and liver is the bet: one Claudin-1 mechanism, several fibrotic diseases.
CSL pays $355M to co-develop Alentis' phase 2-stage fibrosis drug ↗